Drugs / CVXGA50
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06742281 | Dec 2024 → Jun 2026 | COVID-19 | CyanVac LLC | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CVXGA50 | “CVXGA (CVXGA50)” NCT06742281 ↗ |
| Known as | CVXGA | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06742281 ↗ |
| Modality | Vaccine | “CVXGA (CVXGA50) Intranasal COVID-19 Vaccine” NCT06742281 ↗ |
| Route | Intranasal | “receive a single dose of CVXGA (CVXGA50) intranasally” NCT06742281 ↗ |